LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akcijų sąrašas・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

17.37 1.28

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.09

Max

17.49

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-607K -51M
Pardavimai	-28M 100M
Pelnas, tenkantis vienai akcijai	-0.46
Pelno marža	-51.215
Darbuotojai	1,784
EBITDA	4.1M -44M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+88.92% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-541M 1.8B
Ankstesnė atidarymo kaina	16.09
Ankstesnė uždarymo kaina	17.37

Naujienos nuotaikos

By Acuity

34%

66%

88 / 344 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-03 23:22; UTC

Uždarbis

Pagrindinės rinkos jėgos

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

2026-06-03 23:09; UTC

Karštos akcijos

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

2026-06-03 20:51; UTC

Uždarbis

Costco Reports 15% Sales Growth in May

2026-06-03 20:43; UTC

Uždarbis

Broadcom 2Q Revenue Climbs on AI Chip Demand

2026-06-03 23:48; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

2026-06-03 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-03 23:35; UTC

Rinkos pokalbiai

Oil Futures Fall on Possible Technical Correction -- Market Talk

2026-06-03 23:15; UTC

Rinkos pokalbiai

Uždarbis

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

2026-06-03 22:08; UTC

Karštos akcijos

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

2026-06-03 21:54; UTC

Rinkos pokalbiai

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

2026-06-03 21:18; UTC

Uždarbis

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

2026-06-03 21:15; UTC

Uždarbis

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

2026-06-03 21:13; UTC

Uždarbis

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

2026-06-03 21:13; UTC

Uždarbis

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

2026-06-03 21:12; UTC

Uždarbis

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

2026-06-03 21:09; UTC

Uždarbis

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

2026-06-03 21:03; UTC

Uždarbis

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

2026-06-03 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-03 20:43; UTC

Uždarbis

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

2026-06-03 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

2026-06-03 20:37; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

2026-06-03 20:35; UTC

Uždarbis

Broadcom Stock Falls Despite Record Results -- Barrons.com

2026-06-03 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

2026-06-03 20:17; UTC

Uždarbis

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

2026-06-03 20:17; UTC

Uždarbis

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

2026-06-03 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q Adj EPS $2.44 >AVGO

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q EPS $1.91 >AVGO

2026-06-03 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q Rev $22.19B >AVGO

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

88.92% į viršų

12 mėnesių prognozė

Vidutinis 32.4 USD 88.92%

Aukščiausias 44 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Zai Lab Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

88 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.